<DOC>
	<DOCNO>NCT02390713</DOCNO>
	<brief_summary>This ring aim preserve intra-hepatic porto-caval gradient inferior 5 mm Hg major hepatectomy ( 48h ) protect liver initial phase liver regeneration . Morphological feature MID-AVRTM allow intra corporeal open percutaneously removal balloon inflation 5 ml physiological serum . MID-AVRTM develop pig prove efficiency improve liver function 75 % hepatectomy capacity remove percutaneously . Aim feasibility study ( Phase I/II ) prove series 3 evaluable patient ( Phase A ) 6 evaluable patient ( Phase B ) MID-AVRTM could use human without deleterious consequence . In phase A , MID-AVRTM dispose around portal vein major hepatectomy perform healthy liver remove abdominal closure . If phase A result confirm MID-AVRTM well modulate portal pressure easily open remove acute inflation , phase B start . In phase B , MID-AVRTM dispose around portal vein major hepatectomy healthy liver conserve 48 hour remove percutaneously operate room .</brief_summary>
	<brief_title>Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy</brief_title>
	<detailed_description>Preserving liver function vital , especially hepatectomy , main curative treatment liver tumor . An hepatectomy preserve remnant liver volume &lt; 0.5 % body weight associate high risk post-operative liver failure . In situation , liver volume sufficient support local hemodynamic consequence hepatectomy responsible intrahepatic endothelial cell injury impair liver function regeneration . To date , preoperative vein embolization ( PVE ) associate liver transection ( ALPSS procedure ) increase future remnant liver 20 % 90 % method prevent complication . Even preparation necessary moment , PVE increase cancer cell proliferation associate low recurrence free survival without PVE . Despite potential PVE , POLF occur 5 % 7 % major hepatectomy stay first cause death hepatectomy . It demonstrate portal pressure superior 20 mm Hg and/or porto-caval gradient superior 12 mm Hg end hepatectomy associate occurrence POLF . Aim avoid acute intra hepatic portal hypertension associate major hepatectomy associate early liver endothelial cell injury , develop silicon ring dispose around portal vein contain circular inflatable balloon narrow precisely portal vein lumen ( MID-AVRTM ) . Phase A : Tolerance functionality MID-AVR surgery Each procedure film . Phase B : Tolerance functionality MID-AVR surgery Each procedure film .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<criteria>French resident affiliate Social Insurance Major hepatectomy ( Phase A ) Major hepatectomy preserve one hepatic vein ( Phase B ) Remnant liver volume &gt; 0.5 % body weight Age &gt; 80 ( Phase A ) Age &gt; 70 ( Phase B ) Cirrhotic patient ( F4 ) Repeat hepatectomy Patient require portal vein resection History deep venous thrombosis History portal thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hepatectomy</keyword>
	<keyword>post-operative liver failure</keyword>
	<keyword>portal vein</keyword>
	<keyword>portal flow</keyword>
	<keyword>portal pressure</keyword>
	<keyword>modulation</keyword>
	<keyword>surgical device</keyword>
</DOC>